Neurocea

About Us

Neurocea’s lead clinical compound, NP002, is a Phase 3-ready drug being developed for the prevention of falls among Parkinson’s patients and at-risk seniors

Phase 2 study results: Efficacy among Parkinson’s patients​

In a Phase 2 clinical trial, NP002 was effective at reducing falls in Parkinson’s Disease (PD) patients. The trial was designed to evaluate NP002 in the treatment of a movement disorder in PD patients caused by levodopa (L-Dopa), a drug used to treat PD. Results showed NP002 significantly reduced falls in the PD population by improving ambulation and postural stability, without any serious adverse events.

NP002: Leveraging advanced neuroscience

Recent research shows that there is an area in the brain responsible for falls called the Pedunculopontine Nucleus (PPN).* NP002 targets key central nervous system pathways in this part of the brain.

Based on this research and the results of our Phase 2 study, we’re now moving into a pivotal Phase 3 trial. Pending achievement of clinical endpoints, this would allow the drug to be filed for approval for the prevention of falls in Parkinson’s patients and further developed for the same indication in the elderly population at large.

*Bohnen NI, et al, History of Falls in parkinson disease is associated with reduced cholinergic activity, Neurology. 2009;73(20):1670-6. http://dx.doi.org/10.1212/WNL.0b013e3181c1ded6

LEADERSHIP

Our Team

Ari Azhir, Ph.D.
Founder & Board member

Serial biotech entrepreneur, 25+ years of experience as CEO of multiple early-to-late stage biotech. Prior experience in multinational healthcare companies: Intermune, Roche, Becton Dickinson, Connetics, Acuson.

Edgar G. Engleman, M.D.
Founder and Advisory Board Chair

Professor of Pathology and Medicine, Stanford University; Expert in immunotherapy and the immunology of myeloid cells; Founder, Dendreon, Bolt Bio, Medeor; Managing partner, Vivo Capital

William Langston, M.D., Clinical/Medical
Clinical Medical Advisor

Faculty Member at Stanford University and Founder and Scientific Director of the Parkinson’s Institute. Dr. Langston has published nearly 400 scientific papers on PD, and has received numerous national awards for his work.

Matthew Meyer, J.D.
Chief Business Advisor

Corporate attorney and life sciences executive with extensive management, transactional and commercial experience with public and private biopharmaceutical and diagnostics companies: Pfizer, Novartis, CareDx, Myriad Genetics. Currently Head of Business Advisory practice at WSGR.

CONTACT US

We’re seeking partners

We are currently seeking partners to support the development and commercialization of NP002.